Audit brut des composantes de laboratoire de Cairo–Bishop original de 2004 chez l’adulte

État

clinical-review-pending

Version de la méthode

Cairo and Bishop original 2004 adult laboratory-component arithmetic, engine cairo-bishop-2004-adult-same-panel-raw-laboratory-components-v1: from one complete serum panel obtained at one timestamp within the inclusive window from 72 hours before through 168 hours after independently verified cytotoxic-therapy initiation, count one component for serum uric acid >=8.0 mg/dL or >=476 µmol/L, or an increase of at least 25% from its independently selected baseline; one for serum potassium >=6.0 mmol/L or >=6.0 mEq/L, or an increase of at least 25%; one for adult serum inorganic phosphorus >=4.5 mg/dL or >=1.45 mmol/L, or an increase of at least 25%; and one for laboratory-reported source-compatible serum calcium <=7.0 mg/dL or <=1.75 mmol/L, or a decrease of at least 25%. Each component contributes when its native-unit absolute branch or its same-native-unit relative branch is true. The complete baseline panel must independently precede the audited panel, use the same native unit for each paired analyte, and contain no conversion, rounding, inference, imputation, defaulting, or carried-forward value. The original source does not define baseline selection or recency. Requiring all four audited values from one same-time panel is a deliberately narrower product safety rule and is not presented as an original Cairo–Bishop simultaneity requirement. The original and authoritative reproductions label the analyte only as calcium and do not operationalize unadjusted, albumin-corrected, or ionized measurement identity; this workflow requires an independently verified source-compatible laboratory result and the same verified measurement basis at baseline, performs no correction, accepts no albumin input, and substitutes no ionized calcium. Fourteen exact confirmations cover adult status; malignancy and applicable cytotoxic-therapy context; verified treatment-initiation time; one same-time serum panel; the inclusive source window; verified serum analyte, specimen, and native-unit identities; source-compatible calcium measurement basis and inorganic-phosphorus identity; a complete independently selected preceding baseline panel without imputation; acknowledgement that baseline selection and recency are source-undefined; review of the source hydration and hypouricemic-agent assumption; raw arithmetic only without tumor-lysis classification; no delay of urgent assessment, monitoring, or treatment; exclusion of later Howard calcium, AKI, simultaneity, and symptomatic-hypocalcemia variants; and copyrighted-source, independent-implementation, and pending-review limitations. Output is limited to version, the raw integer 0–4 component count, four absolute-branch booleans, four relative-branch booleans, four contribution booleans, and exact entered-value audit. It supplies no laboratory or clinical tumor-lysis-syndrome label, no interpretation when two or more components contribute, no creatinine or acute-kidney-injury assessment, no oliguria, dialysis, arrhythmia, seizure, death, corrected or albumin-adjusted calcium, ionized calcium, grade, cutoff, class, risk, probability, outcome, prognosis, diagnosis, treatment, monitoring, disposition, management, or recommendation.

Population

Qualified clinicians documenting the frozen original 2004 adult laboratory-component arithmetic for a patient age 18 years or older with independently confirmed malignancy and an applicable cytotoxic-therapy context, using one complete verified serum panel obtained at one timestamp from 72 hours before through 168 hours after independently verified therapy initiation and one complete independently selected baseline panel that precedes it. Each baseline pair must retain the same native unit and the verified source-compatible serum-calcium measurement basis; no value may be converted, rounded, inferred, imputed, defaulted, or carried forward. Adult-only use, a complete baseline panel, and a same-time audited panel are deliberately narrower product requirements; the original review supplies no adult age boundary, derivation or validation cohort, baseline-selection or recency method, calcium measurement-basis method, or simultaneity rule. The 2025 British Society for Haematology update reproduces the historical definition while emphasizing current personalized risk assessment, prophylaxis, monitoring, specialist management, and avoidance of delayed treatment. This historical raw audit neither performs nor replaces any of those current clinical duties.

Limites et exclusions

Pediatric use; absent or unverified malignancy, cytotoxic-therapy applicability, treatment-initiation time, or adult status; an audited panel outside the inclusive -72-to-+168-hour window; values from different draws, timestamps, specimens, episodes, or mixed-time panels; or use without independent current clinical assessment. · A missing, unknown, inferred, imputed, defaulted, carried-forward, rounded, converted, or incomplete audited or baseline value; a baseline that does not precede the audited panel; different current-versus-baseline native units or serum-calcium measurement bases; automatic baseline selection; or invention of a baseline recency rule that the original source does not define. · Plasma, urine, whole-blood, or ambiguous specimen substitution; total phosphate or ambiguous phosphate substituted for serum inorganic phosphorus; a calcium result without an independently verified source-compatible laboratory identity and same baseline measurement basis; app-calculated calcium correction; an albumin input; ionized calcium substitution; cross-unit threshold conversion; or altered absolute boundaries, 25% comparisons, window boundaries, component logic, or arithmetic. The source does not specify unadjusted, albumin-corrected, or ionized calcium, so the app does not choose among those bases. · Laboratory TLS, clinical TLS, or any other tumor-lysis-syndrome label; interpreting two or more contributing components; creatinine, renal-insufficiency, acute-kidney-injury, oliguria, dialysis, arrhythmia, seizure, sudden death, clinical toxicity, grade, or severity. Howard 2011 same-24-hour, removal-of-25%-change, symptomatic-hypocalcemia, corrected-calcium, ionized-calcium, and modern AKI variants remain separate and are not calculated. · Any cutoff, class, risk stratification, probability, outcome, mortality, prognosis, diagnosis, treatment eligibility, prophylaxis, rasburicase or other treatment selection or timing, monitoring schedule, admission, transfer, discharge, disposition, management, recommendation, or delay or replacement of urgent oncology, hematology, nephrology, intensive-care, emergency, laboratory, or pharmacy assessment. · Verbatim or adapted reproduction or translation of the 2004 Wiley/Blackwell article, its tables, prose, figures, grading layout, or later copyrighted reproductions; Wiley, Blackwell, British Journal of Haematology, BSH, NHS, or author logos, visual identity, branding, affiliation, or endorsement. The implementation uses independently expressed factual arithmetic and nominative attribution only. The 2004 article is copyrighted and closed-access; clinical and legal review remain pending.

• https://pubmed.ncbi.nlm.nih.gov/15384972/
• https://doi.org/10.1111/j.1365-2141.2004.05094.x
• https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2004.05094.x
• https://doi.org/10.3324/haematol.12327
• https://haematologica.org/article/view/4722
• https://doi.org/10.1056/NEJMra0904569
• https://pmc.ncbi.nlm.nih.gov/articles/PMC3437249/
• https://pubmed.ncbi.nlm.nih.gov/40903841/
• https://doi.org/10.1111/bjh.70092
• https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.70092

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours